Human Tetanus Immune Globulin (HTIG) is a sterile solution of high-titer antibodies (IgG) derived from human plasma. Unlike the tetanus vaccine, which provides long-term “active” immunity by teaching your body to make its own antibodies, HTIG provides “passive” immunity—offering immediate protection by neutralizing the tetanus toxin (tetanospasmin) before it can bind to nerve endings.
Indications for Use:
-
Wound Prophylaxis: Administered to patients with “tetanus-prone” wounds (e.g., deep punctures, burns, animal bites, or wounds contaminated with soil/feces) who have an incomplete or unknown vaccination history.
-
Treatment of Clinical Tetanus: Used as a primary therapeutic agent to treat active cases of tetanus by neutralizing circulating toxins.
-
Emergency Care: Essential for individuals with high-risk injuries who require instant defense against the Clostridium tetani bacteria.
Administration & Safety:
HTIG is administered via intramuscular (IM) injection only. It provides protection for approximately 3–4 weeks. As a prescription drug, it must be administered by a qualified healthcare professional.




